Pathognomonic serum cytokine profiles identify life‐threatening langerhans cell histiocytosis
暂无分享,去创建一个
M. Muraoka | A. Yachie | R. Nishimura | Hideaki Maeba | K. Nomura | Y. Ikawa | K. Noguchi | Masaki Fukuda | Toshihiro Fujiki | Rie Kuroda | Shintaro Mase | Raita Araki
[1] T. Imamura,et al. Recent advances in Langerhans cell histiocytosis , 2014, Pediatrics international : official journal of the Japan Pediatric Society.
[2] A. Yachie,et al. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. , 2013, Cytokine.
[3] B. Chetaille,et al. Protection from Inflammatory Organ Damage in a Murine Model of Hemophagocytic Lymphohistiocytosis Using Treatment with IL-18 Binding Protein , 2012, Front. Immun..
[4] W. Hahn,et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. , 2010, Blood.
[5] U. Pötschger,et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. , 2008, Blood.
[6] P. Di Meglio,et al. Neutralization of Interleukin-18 Inhibits Neointimal Formation in a Rat Model of Vascular Injury , 2006, Circulation.
[7] R. Egeler,et al. Macrophage Activation and Hemophagocytic Syndrome in Langerhans Cell Histiocytosis: Report of 30 Cases , 2002, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.
[8] L. Joosten,et al. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. , 2001, The Journal of clinical investigation.
[9] M. Merad,et al. Pathological consequence of misguided dendritic cell differentiation in histiocytic diseases. , 2013, Advances in immunology.